Rongji Mu

9PUBLICATIONS
18CO-AUTHORS
Pharmaceutical delivery technologiesHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 19, 2026
A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes.

|May 14, 2026
A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization.

|Aug 19, 2025
A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi

|May 09, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.

Si-Yuan Chen, Peng-Peng Xu, Ru Feng

|Dec 24, 2024
Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy.

Nan Wang, Xin-Yun Huang, Xu-Feng Jiang

|Sep 10, 2024
A Bayesian latent-subgroup platform design for dose optimization.

Rongji Mu, Xiaojiang Zhan, Rui Sammi Tang

Pageof 2

Frequent Collaborators

4 joint publications

Weili Zhao

2 joint publications

Ying Yuan

2 joint publications

Jin Xu

1 joint publications

Lei Dong